HOST MODULATION/PERIODONTAL THERAPY EFFECTS ON DIABETES

宿主调节/牙周治疗对糖尿病的影响

• 批准号: 7375329
• 负责人: MARIA E RYAN
• 金额: $ 1.27万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375329
• 关键词: HOST; MODULATION; PERIODONTAL; THERAPY; EFFECTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if the drug Periostat will reduce periodontal disease in persons with Type I diabetes. Periodontal disease causes inflammation of the gums and can result in tooth loss. Periostat is a drug that has been approved by the Food and Drug Administration for the use in the treatment of periodontal disease in non-diabetic persons. It has been shown that when the drug is used, along with standard tooth and root cleaning, non-diabetic patients have greater improvement in their gum disease than patients treated only with tooth and root cleaning. Once the study is concluded we should know if the drug Periostat is useful for the treatment of periodontal disease and whole body inflammation in persons with Type I diabetes.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是确定药物Periostat是否会减少1型糖尿病患者的牙周病。牙周病会引起牙龈发炎，并可能导致牙齿脱落。Periostat是一种经美国食品和药物管理局批准用于治疗非糖尿病患者牙周病的药物。研究表明，当使用这种药物，同时进行标准的牙齿和牙根清洁时，非糖尿病患者的牙龈疾病比只进行牙齿和牙根清洁的患者有更大的改善。一旦研究结束，我们应该知道药物Periostat是否对治疗1型糖尿病患者的牙周病和全身炎症有用。